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Open acSummary Leishmania infantum is endemic in the Maltese archipelago, a group of islands in
the Mediterranean which are visited frequently by tourists from Northern European countries.
The burden of leishmaniasis is highest in children who may present with cutaneous or visceral
manifestations. We describe systematically the manifestations, diagnosis and management of
leishmaniasis in children <14 years of age, who had a histopathological diagnosis of leishman-
iasis in Malta, from 2004 to 2008. Eleven children were diagnosed with leishmaniasis; 8 children
(15e44 months of age) had visceral disease and three (aged 9e13 years) suffered cutaneous
infections. Prolonged high grade fever, pallor, hepatosplenomegaly, and pancytopenia were
common presenting features of visceralisation. Diagnosis was based on the visualisation of
amastigotes from bone marrow aspirates. Pentavalent antimonials were associated with treat-
ment failure in two children, whilst liposomal amphotericin B was curative in all. Children with
cutaneous leishmaniasis had dry crusted ulcero-nodular lesions on exposed areas which re-
sponded to intra-lesional instillation of sodium stibogluconate or to cryotherapy. Leishmaniasis
should be included in the differential diagnosis of fever and hepatosplenomegaly or chronic
cutaneous lesions in children who travel to Malta.
ª 2010 Elsevier Ltd. Open access under CC BY license.fectious Diseases Clinic, Department of Paediatrics, Mater Dei Hospital, Tal-Qroqq, Msida, MSD 2090,
6 2545 4154.
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38 D. Pace et al.Introduction
The leishmaniases are a group of vector-borne protozoan
diseases caused by pathogenic Leishmania species which, if
symptomatic, result in protean clinical manifestations that
range from localised cutaneous ulcers to disseminated lethal
infection. Such diversity is complicated by anthro-
ponozoonotic modes of transmission which follow a sylvatic,
peridomestic or anthroponotic cycle depending on the
mammalian reservoir.1 Being widespread in all continents
(except Australia and Antarctica), but primarily concen-
trated in South Asia, the Horn of Africa, Central and South
America and endemic in the Mediterranean basin, these
parasitoses are a major public health concern.2 Global
annual incidence is estimated at 1.5 million cases of cuta-
neous disease and 500,000 cases of visceral leishmaniasis
(VL), with prevalence rates reaching 12 million.2 Leishman-
iasis is estimated to result in a loss of 1.97 million disability
adjusted life years (DALYs) worldwide, classifying third from
all vector-borne infections.3 In Southern Europe annual
incidence rates of VL, ranged from 0.11 to 8.32/100,000
population from 1998 to 2007.4 In non-endemic countries
leishmaniasis is a disease of travellers and migrants.5
Leishmaniasis is endemic in the Maltese archipelago,
a group of small islands (consisting of Malta, Gozo and
Comino) in Southern Europe with an area of 315 km2,
a population of around 400,000 inhabitants and a pop-
ulation density of 1285 residents per km2, the highest in the
European Union.6 Malta is visited by an average of 1.2
million tourists per year, most of whom come from northern
European countries, namely UK and Germany.6 Cutaneous
and visceral leishmaniases in Malta are caused by a single
species, Leishmania infantum, which is transmitted from
dogs to humans by one local species of sand fly, Phleboto-
mus perniciosus.7 The few studies performed in Malta have
not identified any other Leishmania species in humans who
acquired cutaneous disease in Malta, or in sand flies, dogs
or rats8,9 and because of limited resources species identi-
fication from clinical specimens is not carried out as yet.
InMalta twozymodemes (strainswithdifferent isoenzyme
profiles) of L. infantum have been characterised: MON1 that
causes VL and, as in other Mediterranean countries, is the
commoner form, and MON78 which is dermotropic,8 but
which may cause VL in the immunocompromised.10 Notifi-
cation of leishmaniasis has been compulsory in Malta since
1946, however LCLhadnot been recognised prior 1981 andno
cases were notified before 1983.11 By contrast, VL had been
recognised since 1909,12 with the largest number of cases
(207), being recorded in 1948.13 The quasi-eradication of
stray dogs, improved sanitary conditions and urbanisation
have resulted in a drastic decrease in the incidence of VL
following the SecondWorldWar, from67/100,000 population
in 1948 to 8.2/100,000population in 1955 anddown to amean
of 1.1/100,000 over the last 10 years.13 Rates of cutaneous
disease have remained low since 1983 (mean 1.87/
100,000),14 however, being a non-life-threatening illness and
often not notified or unrecognised, the incidence of LCL is
confounded by underreporting. Children <3 years of age
suffer themajority of the visceral disease burden.15 The case
fatality rate is extremely low with only two individuals, aged
>65 years, dying from VL since 1991.16 Leishmaniasis has notyet been eradicated due to persistent transmission from
canine leishmaniosis,9 the only identified reservoir in Malta,
with 31% (406/1310) of all indirect immunofluorescence (IF)
tests carried out from 2005 to 2008 on dogs with suspected
leishmaniosis being positive.17 The prickly pear (Opuntia
vulgaris) and rubble walls, which are widespread in Malta,
create a perfect habitat for the breeding of sand flies.18
The female phlebotomous sand fly, a 2e3 mm arthropod
belonging to the genus Phlebotomus in the Old World is
a noiseless flier which feeds from dusk throughout the
night.19 Outdoor activities are common in Malta during hot
summer nights (the peak tourist season), putting unaware
individuals at risk of being bitten by P. perniciosus, whose
probing activity is increased when infected.20 Age related
differences in T-cell immunity might contribute to the high
disease burden in children <3 years old. Seasonal variation
of leishmaniasis has not been observed in Malta due to its
variable incubation period (6 weekse6 months but at times
as long as 10 years).15
We describe the manifestations, diagnosis and manage-
ment of leishmaniasis in children, diagnosed in Malta over
a 5 year period, from 2004 to 2008, in order to make
physicians in non-endemic countries aware of the persis-
tence of leishmaniasis in this Mediterranean country.
Leishmaniasis has a wide differential diagnosis and is an
important treatable parasitosis that should be considered in
paediatric travellers returning from endemic regions.
Methods
The hospital records of all children (<14 years) with
a histopathological diagnosis of leishmaniasis from 2004 to
2008, who were identified from the database of the
Pathology Department at Mater Dei Hospital which is the
main acute general hospital in Malta, were reviewed. Eight
children (aged 15e44 months) presented with visceral
leishmaniasis, of which 7 were female. Six children were
Maltese (4 from Malta and 2 from Gozo), and 2 were Somali
(Table 1). The two refugees from Somalia were a boy aged
44 months, who had been living in Malta for the previous 11
months, and an 18 month old girl who had been in Malta for
1 year. Three Maltese children (aged 9e13 years) had
a definite histological diagnosis of cutaneous leishmaniasis
(Table 2). All were male and one lived in Gozo. A single
ulcerated nodule was noted below the left lower eyelid in
the 13 year old boy (Case 10) and on the right arm in the 11
year old boy (Case 11). The 9 year old Gozitan boy (Case 9)
had multiple lesions on his face and right lower limb.
Results
Visceral leishmaniasis
Clinical features
Prolonged high grade fever was observed consistently in all 8
children presenting with VL. Other symptoms included
anorexia, irritability, cough, rhinorrhoea, vomiting and
diarrhoea. All appeared pale and hepatosplenomegaly was
detected in all, except inCase 5,whoonly had splenomegaly.
None exhibited prominent lymphadenopathy. Most children
Table 1 Presentation and management of children with visceral leishmaniasis (2004e2008).
Case number Year Age/
months
Sex Presentation Investigations Treatment Blood
products
Complications Hospital
stay/days
Case 1 Maltese 2004 15 F Febrile up to 40.5 C
for 10 days
Pallor
Hepatosplenomegaly
Pancytopenia
CRP: 143 mg/l
BM: LDBs
Sodium stibogluconate þ
allopurinol  10 days
(switched to Ambisome
[L-AmB] after 20 days)
PC
Platelets
albumin
 Declining platelet counts
down to 2  109/l, causing
epistaxis, diminishing haemo-
globin concentration despite
transfusion, non-resolving
hepatosplenomegaly, devel-
opment of ascites and persis-
tence of fever >38 C after 20
days of antimonials indicated
treatment failure: switched to
L-AmB for 10 days (20 mg/kg)
 L-AmB induced hypokalaemia
30
Case 2 Gozitan 2005 27 F Febrile up to 39.4 C
for 7 days
Pallor
Hepatosplenomegaly
Pharyngitis
Anaemia
Neutropenia
CRP: 207 mg/l
aELISA IgG/IgM: 20.31
BM: LDBs
Sodium stibogluconate þ
allopurinol  10 days
(switched to L-AmB after
14 days)
PC  Generalised macular rash and
recurrence of fever after 10
days of antimonials associated
with pus oozing from cannula
site. Diagnosed with caMRSA
bacteraemia and treated with
teicoplanin for 10 days
 Non-resolving fever 5 days
through teicoplanin and
enlarging spleen indicated
treatment failure: antimonials
switched to L-AmB for 10 days
(30 mg/kg)
18
Case 3 Somalia
(in Malta for
11 months)
2006 44 M Febrile up to 40 C for 7
days
Diarrhoea
Pallor
Hepatosplenomegaly
Anaemia
Thrombocytopenia
CRP: 132 mg/l
IF IgG þ ve, BM: LDBs
Sodium stibogluconate for
21 days
Allopurinol for 10 days
PC  ANA pos 1:80 (fine speckled
nucleolar pattern): not
detected 3 months later
24
Case 4 Gozitan 2007 28 F 7 day h/o fever up to
40C
Clear rhinorrhoea
Miserable
Pallor
Hepatosplenomegaly
Anaemia
Thrombocytopenia
CRP:187 mg/l,
ESR:72 mm/h
IF IgG: þve
BM: LDBs
Sodium stibogluconate for
28 days
Allopurinol for 10 days
Nil Nil 11
Case 5 Maltese 2007 19 F Febrile up to 39 C for 4
days
Pallor
Splenomegaly
Pancytopenia:
CRP:100 mg/l,
ESR: 56 mm/h
ELISA IgG/IgM: 20.3,
BM: LDBs
Sodium stibogluconate for
21 days
Allopurinol for 10 days
PC Nil 5
(continued on next page)
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Table 1 (continued)
Case number Year
Age/
months Sex Presentation Investigations Treatment
Blood
products Complications
Hospital
stay/days
Case 6 Maltese 2007 16 F Recurrent URTIs during
the previous 4 months
Poor weight gain,
Febrile up to 38.2 C in
hospital,
Irritable
Pallor
Hepatosplenomegaly
Pancytopenia
Direct Coombs test:
þve
BM: LDBs
L-AmB for 10 days
(30 mg/kg)
PC Nil 4
Case 7 Maltese 2008 20 F Febrile up to 40.2 C
for 7 days
Rigors
Irritable
Pallor
Hepatosplenomegaly
Pancytopenia
CRP 29 mg/l
IF IgG þ ve
ELISA IgG/IgMeve
BM: LDBs
PCR: L. infantum þve
L-Amb for 10 days
(20 mg/kg)
Nil Nil 11
Case 8 Somalia
(in Malta for
1 year)
2008 18 F Febrile up to 40.3 C
for 3 weeks
Refusing to walk
Pharyngitis,
Hepatosplenomegaly
Pancytopenia
CRP 114 mg/l
IF IgG þve
ELISA IgM/IgG: 20.7
BM: LDBs
L-Amb for 10 days
(20 mg/kg)
PC Nil 11
Abbreviations: M: male, F: female, URTI: Upper respiratory tract infection, CRP: C-reactive protein, BM: Bone marrow aspirate, LDBs: Leishman-Donovan bodies, ELISA: Enzyme-Linked
Immunosorbent Assay, IF: Indirect immunofluorescence assay for L. infantum IgG; ESR: Erythrocyte sedimentation Rate, PCR: polymerase chain reaction, PC: packed cells, ANA: Anti-
Nuclear Antibodies.
a Values for ELISA represent an antibody index with a cut off >11 taken as positive.
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Leishmaniasis in children in Malta 41appeared well between episodes of fever and none had signs
of septic shock or disseminated intravascular coagulation.
Laboratory findings
Pancytopenia was a frequent but inconsistent finding with
total white cell counts of 2.3e5.9  109/l, neutrophils as
low as 0.22  109/l (range 0.22e2.8  109/l), haemoglobin
concentration of 5.3e9.5 g/dl with microcytic, hypo-
chromic red cells, and platelet counts of 34e157  109/l.
High C-reactive protein (range: 29e207 mg/l), an ESR
>40 mm/h, hypoalbuminaemia and negative blood cultures
were observed consistently. A bone marrow aspirate was
diagnostic in all (Fig. 1) and excluded any underlying hae-
matological malignancy. Serological testing using an IF
assay for anti-L. infantum IgG (Leishmania-Spot IF, bio-
Me´rieux, Marcy l’Etoile, France)21 and/or an indirect
enzyme-linked immunosorbent assay (ELISA) for anti-L.
infantum IgG þ IgM (Vircell, S.L., Granada, Spain)22 were
performed. All children tested had a positive IF assay but
ELISA was falsely negative in Case 7 who, subsequently, was
confirmed to be infected with L. infantum using a poly-
merase chain reaction (PCR) assay detecting the species
specific genome regions SSUrRNA and ITS-1. The two Somali
refugees were presumed to have acquired the infection in
Malta; however, species identification was not performed.
Anti-nuclear antibodies were detected transiently in case
3.
Treatment
Sodium stibogluconate (Pentostam, GlaxoSmithKline, Mid-
dlesex, UK) at a dose of 20 mg/kg for 21 days (preceded by
an initial test dose of 25 mg) in combination with oral
allopurinol (20 mg/kg daily for 10 days) was the treatment
of choice prior 2007. Liposomal amphotericin B (L-AmB,
AmBisome, Gilead Sciences Int. Ltd, Cambridge, UK) at
a total dose of 20e30 mg/kg administered over 10 days, was
preferred subsequently in view of concerns on treatment
failure with antimonials. Most children received a blood
transfusion for anaemia since the haemoglobin concentra-
tion is known to drop in the first 2 weeks of treatment.15
The microcytosis, possibly resulting from associated iron
deficiency, generally resolved after treatment and none
had an underlying haemoglobinopathy. Case 1 needed
multiple platelet transfusions due to recurrent epistaxis as
a result of thrombocytopenia (dropping to 2  109/l) asso-
ciated with treatment failure. Because of the underlying
neutropenia, many children were started on antibiotics on
admission. The caMRSA bacteraemia in Case 2, resulting
from an infected intravenous cannula, was associated with
an appropriate neutrophilic response.
Response to treatment
Successful treatment resulted in defervescence (noted
within 2e8 days) which coincided with a rise in the platelet
count, whilst unremitting fever or its recrudescence,
a decreasing platelet count or non-resolving hep-
atosplenomegaly indicated treatment failure (Case 1: a 15
month old Maltese girl and Case 2: a 27 month old girl from
Gozo: Table 1). Hospital stay for children showing an
immediate response was short (4e11 days) and the full
treatment course was subsequently completed as outpa-
tients. Because of the language barrier and social
Figure 1 Bone marrow smears from Case 3 (Giemsa stain 1000). a) Intra-macrophageal Leishman-Donovan bodies; b) Ruptured
macrophage with release of several amastigotes, c) Extracellular amastigote with prominent nucleus and kinetoplast, d) Cyst-like
structure (arrow) containing amastigotes. Source: Haematology Department, Mater Dei Hospital, Malta.
Figure 2 Cutaneous leishmaniasis (Case 11): Raised
erythematous nodule (diameter of 1 cm) with central dry
ulceration and surrounding inflammatory hypopigmentation on
the right lateral arm. Source: MJB, Dermatology Department,
Sir Paul Boffa Hospital, Floriana, Malta.
42 D. Pace et al.background, the two Somali children were kept in hospital
to ensure treatment compliance. Treatment failure was
associated with a prolonged hospital stay (18e30 days).
Despite their documented toxicities, no complications were
associated with antimonials and the hypokalaemia
observed in Case 1 was induced by L-AmB. All children were
followed up for 6e12 months and none developed any
clinical signs of relapse.
Localised cutaneous leishmaniasis (LCL)
Clinical presentation
The three boys presenting with cutaneous disease had
crusted ulcero-nodules (<1.5 cm in diameter) on exposed
areas namely on the face, arm (Fig. 2) and legs, with Case 9
having multiple lesions (Table 2). Diagnosis was delayed in
Cases 9 and 10 for 3 months and 2 years, respectively since
the disease was not recognised, whilst Case 11 was
promptly diagnosed at presentation. Case 9 received local
antimicrobial treatment for suspected fungal lesions and
was also prescribed oral flucloxacillin for possible impetigo.
Similar treatment was administered to Case 10 on whom
incision and curettage of the ‘cyst-like’ lesion was also
inappropriately attempted with no success.
Laboratory findings
Histological examinationof tissue specimenswas diagnostic in
all. Diagnosis of LCL in Case 10 (Fig. 3) was only clinched after
his skin lesion was ultimately excised, 2 years after onset, forpsychological distress. Slit skin smears performed on case 11
did not reveal the Leishmania amastigotes, however, similar
to Case 9, a punch biopsy of the lesion was diagnostic.
Treatment
The management of all three cases was different: Case 9
received cryotherapy with liquid nitrogen in view of the
Figure 3 Histology of cutaneous leishmaniasis in Case 10 (H&E stain): a) Diffuse chronic inflammatory cell infiltrate in dermis
with multiple non-caseating granulomata (40); b) Tuberculoid-type granulomata with central histiocytes and peripheral
inflammatory cells (100); c) Leishman-Donovan bodies (arrows) within cytoplasm of epithelioid histiocytes (600); d) Langhans
type giant cells (arrows) within a granuloma (600). Source: Pathology Department, Mater Dei Hospital, Malta.
Leishmaniasis in children in Malta 43multiplicity of his lesions, the surgical procedure carried
out on Case 10 was curative and Case 11 received repeated
intra-lesional injections of sodium stibogluconate. All
treatment modalities resulted in clinical cure and although
Case 10 had a residual surgical scar he had no recurrence.
Discussion
The clinical manifestations of the children described in our
study are typical of the presentation of childhood VL in
developed countries in the Mediterranean littoral.23e26 By
contrast, VL in children in Albania, a less industrialised
Mediterranean countrywith amuch higher incidence rates of
VL (reaching up to 25/100,000 in 0e6 year old children), is
more frequently complicated by concurrent infections such
as bronchopneumonia and diarrhoea.27 This variable clinical
expression of leishmaniasis not only depends on the inocu-
lated zymodeme and efficacy of the immune response, but is
also affected by environmental factors and the genetic
constitution of the host.28 Cryptic infections caused by vis-
cerotropic Leishmania species are also common.29
The hepatosplenomegaly observed in our children with
VL is a result of the accumulation of mononuclear phago-
cytic cells which causes hyperplasia of reticulendothelial
cells. Pancytopenia occurs secondary to bone marrowinvolvement and hypersplenism. Concurrent viral infections
and occasionally life-threatening bacterial sepsis may occur
secondary to the associated immunosuppression.30
Untreated VL is fatal within 2e3 years. Persistence of
Leishmania is characteristic, and although none of the
children in our case series relapsed, relapses can poten-
tially occur up to 6e12 months after treatment.
Diagnosis of VL in our study was clinched by demon-
stration of amastigotes by light microscopy of bone marrow
smears, with all children having intracellular amastigotes,
known as Leishman-Donovan bodies (Fig. 1). Interestingly,
an extracellular cyst-like structure (Fig. 1d) was noted only
in children receiving antibiotics at the time of sampling.
The well defined circular outline of the structure, as well as
the regular arrangement of the amastigotes within and the
staining characteristics of the interspersed material, makes
it unlikely to represent cytoplasmic fragmentation of
a macrophage that may occur during smearing. This finding
has never been described previously and although its origin
is unexplained, could plausibly be a response to an adverse
milieu created by the antibiotics. Electron microscopy
could perhaps elucidate its morphology and significance.
Although not performed in our study, light microscopy of
splenic or lymph node smears may alternatively be used for
diagnosing VL. We avoided splenic aspirates due to the
44 D. Pace et al.potential risk of death from massive bleeding associated
with thrombocytopenia, a frequent haematological mani-
festation in Maltese children with VL. Lymph node smears
were not indicated as none of the described children had
lymphadenopathy. Leishmania may be cultured on a Novy-
McNeal Nicolle medium but this is not done routinely in
several countries due to the required expertise and cost.
Despite lacking standardisation conserved sequences in
minicircle kinetoplast DNA or in the small subunit rRNA
gene of Leishmania may be detected rapidly by PCR on
lymph node and bone marrow aspirates (Case 7), on
peripheral blood31 or on urine.32
Some of our children with VL had anti-Leishmania anti-
bodieswhich are useful diagnostically but arenot protective,
probably due to the obligate intracellular nature of the
parasite. Their detection by IF, ELISA orWestern blotmust be
correlated with clinical findings since false positives may
occur in asymptomatic or resolved Leishmania infections and
in other infectious diseases.33 Molecular mimicry of Leish-
mania antigens, in addition to polyclonal B-cell activation,
may result in the production of autoantibodies to ribonu-
cleoproteins (Case3), rheumatoid factor and smoothmuscle,
and may be responsible for a positive Coombs’ test (Case
6).34,35 Autoantibodies, which are generally non-pathogenic,
may play a yet undefined role in protection but can cause
diagnostic confusion with connective tissue disorders.36 The
detection of serum anti-rK39 (an amino acid repeat that is
conserved within the L. donovani complex) IgG37 or low
molecular weight antigen (LMWA), thought to be a carbohy-
drate antigen derived from amastigotes, in urine38 are
alternative tests used for the rapid diagnosis of VL.
The Maltese children with LCL had ‘dry’ nodulo-ulcera-
tive lesions (Fig. 2) typical of L. donovani complex disease.
Diagnosis was based on the visualisation of amastigotes on
direct microscopy of skin smears (Fig. 4) or of punch/ellipse
skin sections (Cases 9e11). Because of its benign presen-
tation, LCL in children in Malta tends to be treated in the
community with cryotherapy without an attempt for
a histopathological diagnosis and without notification. PCRFigure 4 Cytology of slit skin smear showing extracellular
and intracellular (within epithelioid histiocyte) amastigotes
(Giemsa stain 600). Source: Pathology Department, Mater Dei
Hospital, Malta.has improved the sensitivity of microscopy and can identify
the infecting species, but is costly and not done in Malta.39
The utility of serology is limited due to the low titres of
antibodies induced in LCL and therefore we do not perform
anti-Leishmania antibodies for children with LCL.39 The
leishmanin (Montenegro) skin-test, reflecting cell-mediated
immunity, may be used but cannot distinguish between past
and present infection.39
Parenteral pentavalent antimonials have been the
standard treatment for both cutaneous and visceral disease
for the last 50 years; however, the associated toxicity, long
treatment duration (20e28 days) and the development of
resistance from irregular compliance have led to the uti-
lisation of alternative drugs.40 As in Malta, lipid formula-
tions of amphotericin B are nowadays more commonly used
in Southern Europe due to their cost effectiveness when
administered in short course regimens that results in
a reduced hospital stay which offsets their high cost.41
Alternative agents such as the aminoglycoside paromomy-
cin, is expected to provide a cheaper but efficacious
alternative to amphotericin B.42 Furthermore, miltefosine,
the only oral formulation that has proven efficacy in chil-
dren,43 may be used as outpatient therapy to treat VL,
although non-compliance is a concern.
Although cutaneous lesions may be observed expectantly
as most would heal spontaneously within months, time to
resolution varies between species and individuals. Intra-
lesional antimony regimens administered between 1 and 3
times weekly for 2e8 weeks (Case 11) are effective, but
painful. The local application of paromomycin ointment,44
cryotherapy45 or thermotherapy,46 are attractive options
devoid of systemic side effects, however, the success rate is
variable and species dependent. Prolonged and cosmetically
significant or multiple lesions may be treated with paren-
teral antimonial compounds, amphotericin B, petamidine
and oral miltefosine. Most of these treatment options have
been poorly investigated in clinical trials and the need for
proper research assessing the long term effects of such
regimens, particularly in children, is still there.47
Being an island there are several public health measures
that can be implemented effectively to eradicate leish-
maniasis fromMalta. Control measures on the importation of
dogs are already in place making it very unlikely for the
introduction of L. infantum from neighbouring endemic
Mediterranean countries. However, the current veterinary
practice of treating infected pet dogs with antimonials
severely limits the control of canine leishmaniosis, since dogs
are known to have high rates of relapse.48 In addition such
practice promotes drug resistance48 and is very likely the
reason for the treatment failures with antimonials seen in
some of the children in our study. In the absence of a culling
program for infected dogs prospects for eradication of
leishmaniasis are bleak, although its implementation is likely
to be met with resistance from dog owners and animal rights
groups.
Conversely, the promotion of deltamethrin-impregnated
dog collars would be effective in preventing canine leish-
maniosis and may result in a reduction in VL.49 Although
vaccine prevention of leishmaniosis in dogs by means of
Leishmune, the only licensed canine vaccine that is
currently in use in Brazil is attractive, its impact on the
epidemiology of zoonotic VL in humans is still unknown.50
Leishmaniasis in children in Malta 45Vector control by indoor residual spraying of insecticides
is unpopular51 and only has a transient effect due to the
predominant exophagic and exophilic nature of most
phlebotomous sand flies, whilst outdoor spraying is inef-
fective.19 Breeding ground destruction by removal of rubble
walls is illegal since these are part of the Maltese heritage
and are protected. In Malta the wide distribution of
Opuntia trees found growing wildly or else being cultivated
for their fruit from which a characteristic liqueur is also
manufactured, makes their eradication challenging.
At present avoiding sand fly bites is the most practical
advice that can be given to tourists visiting Malta in order to
prevent leishmaniasis. The application of insect repellents
on children who will be spending time outdoors after dusk
and before dawn, as is common during recreational activi-
ties in summer in Malta, is encouraged. For those who
prefer to sleep with the windows open, insect screens are
recommended as these will help prevent getting bitten by
sand flies indoors during sleep. Sleeping in storeys above
the first floor is effective in avoiding sand fly biting as sand
flies are poor fliers and can only hop a vertical distance of
1 m.52 Immunisation against leishmaniasis is not possible at
present since despite a century of research no effective
vaccine is available to protect against human leishmaniasis.
Conclusion
The manifestations of leishmaniasis described in this case
series highlight the persistence of this parasitosis in Malta.
The small contained size of Malta creates an opportunity
for eradication of leishmania which is, however, hindered
by the persistence of chronically infected dogs. Clinical,
epidemiological and entomological studies of leishmaniasis
in this country are needed. Eliminating the threat of
leishmaniasis would not only be beneficial for the Maltese
population but also for the tourist industry which is a major
source of income for Malta. Unfortunately leishmaniasis is
perceived as non-profitable by pharmaceutical companies
and failing industrial interest and investment in research,
especially in developing countries, leishmaniasis will
remain a neglected disease.
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